Skip to content
Market Spectator

Market Spectator

Primary Menu
  • Business
  • Domestic
  • Economy
  • Politics
  • Top News
  • Newsletters
Live
  • Home
  • 2026
  • September
  • 29
  • Kodiak Sciences Proved Its Eye Drug Works. Now the Question Is Dosing.
  • Money

Kodiak Sciences Proved Its Eye Drug Works. Now the Question Is Dosing.

With 54% of Zenkuda patients at six-month dosing and a Q4 BLA plan, the stock surge may be the start, not the end.
Market Spectator September 29, 2026 4 minutes read
a3525ad6-4a9d-4808-95ee-06b1b68cda30

Half the investment thesis in retinal medicine has always been the needle. Patients with wet age-related macular degeneration endure injections directly into the eye, typically every eight weeks on Eylea after the initial monthly doses, sometimes more often. Cutting that burden in half is not a quality-of-life footnote. It reshapes which drug a retina specialist reaches for first. That is the question Kodiak Sciences answered on Monday, and it is what the stock surge is really pricing.

Kodiak Sciences announced that the primary endpoints were met for both Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501) in the Phase 3 DAYBREAK study in patients with wet age-related macular degeneration. Both Zenkuda and tabirafusp-ted achieved non-inferiority in vision gains compared to aflibercept at year one. The vision math is settled. The durability math is what matters next.

Among Zenkuda patients, 54% reached 24-week dosing intervals at one year under strict criteria requiring retreatment when retinal fluid appeared. That last clause matters. This was not a liberal retreatment protocol designed to flatter the durability numbers. Patients on aflibercept received treatment every eight weeks throughout the maintenance phase. Zenkuda’s majority-on-six-months result was achieved while holding patients to a tighter standard, not a looser one.

The positive results, especially the strong performance of Zenkuda noted by retinal specialist Dr. Charles Wykoff in Kodiak’s announcement, suggest that Kodiak’s Antibody Biopolymer Conjugate platform may deliver longer-lasting treatments than current anti-VEGF therapies. No patients experienced intraocular inflammation after treatment with Zenkuda, and 0.5% experienced cataracts, versus 0.9% in the aflibercept treatment arm. That clean safety profile matters especially because an unexpected increase in cataracts in earlier tarcocimab Phase 3 studies helped derail the program in 2023. The program was resurrected. Monday’s data closes that chapter.

The Commercial Case

Zenkuda and KSI-501 are aimed at the large anti-VEGF market across retinal vascular diseases, which analyst estimates have put at over $15 billion in annual global sales in recent years. If approved, Zenkuda will compete with blockbuster wet AMD sellers like Eylea and Roche’s Vabysmo. Roche’s Vabysmo reached roughly four-month dosing for about half of patients in its pivotal trials. Zenkuda just showed six-month dosing for the majority, under tougher criteria. That differentiation is the core of the commercial argument.

The results bring Zenkuda’s total to five positive Phase 3 studies spanning wet AMD, diabetic retinopathy, and macular edema following retinal vein occlusion, with Kodiak planning to submit Zenkuda data to regulatory authorities in the fourth quarter of 2026, seeking approval across all three conditions. A three-indication BLA plan this quarter is not a minor regulatory step. It is the event that transforms Kodiak from a clinical-stage story into a commercial story.

What Could Go Wrong

Kodiak is still burning cash. For Q2 2026, the company posted a net loss of $65.6 million, driven mainly by research and development expense of $56.1 million. In its 10-Q for the quarter, Kodiak reported net cash used in operating activities of $86.2 million for the first six months of 2026. Kodiak is still precommercial, so the next things to watch are FDA approval, how it funds a launch, and KSI-101’s Phase 3 data in December 2026. Building a retinal sales force from scratch against entrenched Regeneron and Roche franchises is a different problem than winning a clinical trial.

There is also a detail gap. Kodiak has not yet shared detailed DAYBREAK data beyond the topline description, including its description of a strong early clinical effect through the loading phase. Full data presented at a medical conference could push the stock either direction.

What to Watch Next

Multiple Kodiak catalysts cluster into year-end, including an October look at the DAYBREAK dataset at the American Academy of Ophthalmology meeting and December 2026 readouts for KSI-101. The October American Academy of Ophthalmology meeting will be where retina specialists see the full DAYBREAK dataset. Their reception, not Wall Street’s one-day reaction, will determine whether Zenkuda earns prescriptions. FDA approval timelines and the specifics of partnership or financing deals will follow. A drug that requires one injection every six months instead of every eight weeks does not need to take a large share of the market to justify the current valuation. It needs to prove physicians believe those durability numbers hold in the real world.

Post navigation

Previous: Meta, Amazon, Alphabet, and Microsoft Now Have a Tax Problem
Next: Goldman Sachs Is Down With the Group. That May Be the Buy.

Related Stories

830d540e-5ce2-4571-8954-419bf120eb64
  • Money

Lowe’s Reports Tomorrow. The Stock Is 27% Off Its Low.

Market Spectator November 17, 2026
812ff6f2-7788-4db6-8e63-5fd9858563ca
  • Money

Allianz Raised Its 2026 Profit Target to €18.6bn. PIMCO Drove the Beat.

Market Spectator November 12, 2026
990ed45e-7415-4bc4-8dfb-fa1228770cb2
  • Money

Lyft’s Hidden Asset Is Worth More Than Its Stock Price

Market Spectator November 11, 2026

Live Market Pulse

The charting technology is provided by TradingView. Learn how to use theTradingView Stock Screener.

Recent Posts

  • AMD Is 20% Off Its High. The Anthropic Deal Just Changed the Math.
  • Taiwan’s Taiex Lost 17.5% This Week. The Curbs Did Not Work.
  • Gold Is Down 3% and the Dollar, Yields, and Miners Agree
  • Brent Was Already Falling Before Shenzhen. Hormuz Confirms Why.
  • Brent Was Already Falling Before Shenzhen. Hormuz Confirms Why.
  • Klarna’s Margins Are Outrunning Its Losses
  • CG Oncology’s Trial Win Is Real. Buying the Stock Now Is Different.

Categories

  • Business
  • Economy
  • Money
  • Newsletters
  • Politics
  • Top News

You may have missed

54ebadaa-8092-44e3-9739-092f23897cc5
  • Politics

AMD Is 20% Off Its High. The Anthropic Deal Just Changed the Math.

Market Spectator November 20, 2026
5e1bee43-1d20-4cfb-aa79-5634e142f745
  • Top News

Taiwan’s Taiex Lost 17.5% This Week. The Curbs Did Not Work.

Market Spectator November 20, 2026
2def7e82-efef-4428-81e8-f4b53769c3a6
  • Politics

Gold Is Down 3% and the Dollar, Yields, and Miners Agree

Market Spectator November 19, 2026
d71a93d4-cd57-4c87-b378-2bcc88812788-1
  • Newsletters

Brent Was Already Falling Before Shenzhen. Hormuz Confirms Why.

Market Spectator November 19, 2026
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms of Service/Use Agreement
  • Contact Us
Copyright 2026 © All rights reserved | Market Spectator | marketspectator.com SITE_OK